Sensus Healthcare Plunges 21.5% on Q2 Loss, Revenue Drop

Generated by AI AgentAinvest Pre-Market Radar
Friday, Aug 8, 2025 5:49 am ET1min read
Aime RobotAime Summary

- Sensus Healthcare’s stock plummeted 21.5% pre-market after reporting a $0.06/share Q2 loss and 20.7% revenue decline to $7.3M.

- Adjusted EBITDA turned negative $1.8M, underscoring ongoing financial struggles despite long-term market optimism.

- Analysts remain cautiously optimistic about its non-invasive skin cancer treatment market potential amid short-term challenges.

On August 8, 2025,

experienced a significant drop of 21.5% in pre-market trading, marking a notable decline in its stock performance.

Sensus Healthcare reported a quarterly loss of $0.06 per share for the second quarter of 2025, falling short of the estimated $0.01 per share. This financial setback was accompanied by a 20.7% decline in revenue compared to the same period in 2024, with Q2 2025 revenue totaling $7.3 million, significantly below the $9.3 million estimate.

The company's adjusted EBITDA for the quarter was negative $1.8 million, further highlighting the financial challenges faced by Sensus Healthcare. Despite these setbacks, analysts remain cautiously optimistic about the company's long-term prospects, particularly in the non-invasive skin cancer treatment market.

Comments



Add a public comment...
No comments

No comments yet